Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Sickle Cell Disease Weight between 50 and 120 kg Karnofsky performance status (KPS) ≥70% Confirmed diagnosis of sickle cell disease with βS/βS or βS/β0 or βS/β+ genotype Must have had one or more of the following events in the 2 year period preceding enrollment History of ≥2 severe vaso-occlusive pain crises (VOC) (or at least two episodes in the year preceding the setting up of regular transfusion protocol). A severe VOC is defined as an episode of pain lasting more than 2 hours severe enough to require care at a medical facility History of ≥1 episodes of acute chest syndrome despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea) Clinically significant neurological event (stroke) or any neurological deficit lasting 24 hours. A stroke is defined as a sudden neurological change lasting more than 24 hours that is accompanied by cerebral magnetic resonance imaging (MRI) changes Prior treatment with regular RBC transfusion therapy, defined as receiving ≥8 transfusions per year for >1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome) Osteonecrosis of two or more joints Anti-erythrocyte alloimmunization (>2 antibodies)  Diagnosed with alpha thalassemia (two or more gene deletions or any α-globin structural variants) Seropositivity for HIV-1/2 (Human Immunodeficiency Virus) or HTLV-1/2(Human T-Lymphotropic Virus) Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to treatment. Participants with fever should await resolution of symptoms before starting the treatment Any clinically significant active infection which, in the opinion of the investigator, would require significant medical intervention Abnormal pulmonary function tests (adults with mild or moderate obstruction or restriction or diffusion defects are eligible, per Investigator discretion) History of pulmonary hypertension, proven by cardiac catheterization History of malignancy or immunodeficiency disorder, (i.e., subjects with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma or cutaneous squamous cell carcinoma Participation in any study with an investigational agent or medical device within 90 days of screening Major surgery in the past 30 days Prior receipt of any gene transfer product